TSX · ACB.TO
Aurora Cannabis Inc.
CA$5.74+CA$0.03 (+0.53%)
Aurora Cannabis Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.4% below the high.
Loading market information…
XETRA · C6O.DE · EUR
Stock price, earnings
Quote as of Dec 15, 2022, 04:35 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Clovis Oncology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.97% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Clovis Oncology, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Clovis Oncology, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of anti-cancer agents, serving markets in the United States, Europe, and globally. Its flagship commercial product in the U.S. is Rubraca (rucaparib), an oral small molecule designed to inhibit poly ADP-ribose polymerase. This treatment is indicated for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, Rubraca is offered for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The company's pipeline includes lucitanib, an investigational angiogenesis inhibitor that targets vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3). Also under development is FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent that specifically acts upon fibroblast activation protein. Rubraca is distributed through a select network of specialty distributors and pharmacies, which then supply the medication to patients and healthcare providers. Clovis Oncology has established strategic collaborations, including license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH. The company also maintains a clinical collaboration with Bristol Myers Squibb Company and a partnership with Foundation Medicine, Inc. Founded in 2009, Clovis Oncology, Inc. is headquartered in Boulder, Colorado.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:19 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
21 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CA$5.74+CA$0.03 (+0.53%)
Aurora Cannabis Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.4% below the high.
$0.77-$0.16 (-16.89%)
Inovio Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.63% below the high.
€2.64-€0.16 (-5.71%)
ifa systems AG’s quoted price sits in the lower half of its reported 52-week range, 44.54% below the high.
€0.25€0.00 (0.0%)
co.don AG’s quoted price sits in the lower half of its reported 52-week range, 89.57% below the high.
€0.02€0.00 (0.0%)
BZAM Ltd.’s quoted price sits in the lower half of its reported 52-week range, 88.28% below the high.
€0.13-€0.05 (-27.64%)
Medigene AG’s quoted price sits in the lower half of its reported 52-week range, 96.79% below the high.
€0.87€0.00 (0.0%)
Epigenomics AG’s quoted price sits in the lower half of its reported 52-week range, 45.28% below the high.
€0.32€0.00 (0.0%)
CytoTools AG’s quoted price sits in the lower half of its reported 52-week range, 90.93% below the high.
